COLL Collegium Pharmaceutical Inc.

Collegium to Participate in Upcoming Investor Conferences

Collegium to Participate in Upcoming Investor Conferences

STOUGHTON, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) --  (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that management will participate in the following investor conferences:

Jefferies London Healthcare Conference

Fireside Chat Date and Time: Tuesday, November 19, 2024, at 1:30 p.m. GMT

Piper Sandler 36th Annual Healthcare Conference

Fireside Chat Date and Time: Thursday, December 5, 2024, at 1:00 p.m. ET

The fireside chats will be webcast live and can be accessed from the Investors section of the Company's website: . A replay of the webcast will be archived on the Company's website for 90 days following the presentation.

About Collegium Pharmaceutical, Inc.

Collegium is a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions. Collegium’s headquarters are located in Stoughton, Massachusetts. For more information, please visit the Company’s website at .

Investor Contact:

Danielle Jesse

Director, Investor Relations

Media Contact:

Marissa Samuels

Vice President, Corporate Communications



                                                        





EN
12/11/2024

Underlying

COLLCollegium Pharmaceutical Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Collegium Pharmaceutical Inc.

 PRESS RELEASE
Free
COLL Collegium Pharm...

Collegium to Present Nine Real-World Data Posters at PAINWeek 2025 Ann...

Collegium to Present Nine Real-World Data Posters at PAINWeek 2025 Annual Meeting STOUGHTON, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: COLL) today announced it will present nine posters showcasing real-world data from its differentiated pain portfolio at PAINWeek 2025, taking place in Las Vegas, NV, September 2-5, 2025. The posters will highlight real-world data from the company’s portfolio of pain treatments and reflect Collegium’s continued commitment to responsible pain management. “We are pleased to present this new research to the pain care community,” said Thomas Smith, M....

August 25, 2025 1 EN
Free Trial
COLL Collegium Pharm...

Collegium Pharmaceutical Inc: 1 director

Two Directors at Collegium Pharmaceutical Inc sold after exercising options/sold 29,861 shares at between 37.850USD and 38.034USD. The significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trad...

COLL COLLEGIUM PHARMACEUTICAL INC.
08/16/25 August 16, 2025 1 EN
 PRESS RELEASE
Free
COLL Collegium Pharm...

Collegium Reports Second Quarter 2025 Financial Results; Raises 2025 O...

Collegium Reports Second Quarter 2025 Financial Results; Raises 2025 Outlook – Generated Record Quarterly Net Revenue of $188.0 Million, Up 29% Year-over-Year – – Generated Record Quarterly Jornay PM® Net Revenue of $32.6 Million and Grew Prescriptions by 23% Year-over-Year – – Generated Net Revenue of $155.4 Million from the Pain Portfolio, Up 7% Year-over-Year with All Three Core Products Recording Revenue Growth in the Quarter – – Raised Full-Year 2025 Net Revenue Guidance to be in the Range of $745 to $760 Million and Adjusted EBITDA Guidance in the Range of $440 to...

August 7, 2025 1 EN
 PRESS RELEASE
Free
COLL Collegium Pharm...

Collegium to Report Second Quarter 2025 Financial Results on August 7,...

Collegium to Report Second Quarter 2025 Financial Results on August 7, 2025 STOUGHTON, Mass., July 24, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: COLL) today announced that it will report second quarter 2025 financial results before the market opens on Thursday, August 7, 2025. Following the release of the financials, the Company will host a live conference call and webcast at 8:00 a.m. ET. Conference Call Information To access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the “Collegium Pharmaceutical Q2 2025 Earnings Call.” An audio webc...

July 24, 2025 1 EN
 PRESS RELEASE
Free
COLL Collegium Pharm...

Collegium Announces $150 Million Share Repurchase Program

Collegium Announces $150 Million Share Repurchase Program STOUGHTON, Mass., July 07, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: COLL), a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced its Board of Directors has authorized a new share repurchase program to repurchase up to $150 million in common stock through December 31, 2026. This program replaces a previous $150 million share repurchase program authorized in January 2024 which expired on June 30, 2025, and had $65 million remaining under the progr...

July 7, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch